Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Epidiolex | cannabidiol | Dravet Syndrome (DS) | Reimburse with clinical criteria and/or conditions | Active | ||
Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Reimburse with clinical criteria and/or conditions | Active | ||
Leqvio | inclisiran | Primary hypercholesterolemia | Active | |||
Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Active | ||
Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Reimburse with clinical criteria and/or conditions | Active | ||
Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Active | ||
Ultomiris | ravulizumab | Neuromyelitis optica spectrum disorder (NMOSD) | Reimburse with clinical criteria and/or conditions | Active | ||
Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Active | |||
Eylea HD | aflibercept 8mg/0.07mL | diabetic macular edema | Active | |||
Uplizna | inebilizumab | Neuromyelitis optica spectrum disorders (NMOSD) | Reimburse with clinical criteria and/or conditions | Active |